Invitae Corporation (NYSE:NVTA) shares are trading lower this Wednesday after the company reported fourth-quarter financial results and provided guidance for full-year 2023. The company also announced ...

Invitae has high short interest, estimated at 17.2%. The Federal Reserve just raised interest rates, making it tougher for companies like Invitae to raise cash. Invitae is burning tons of cash right ...

Invitae reported that revenue grew 17.5%, year over year. The stock is still down more than 64% this year. Invitae said it has enough cash to last it through 2024. The company's second-quarter numbers ...

A little more than two years after California genetics-testing company Invitae Corp. (NYSE: NVTA) bought ArcherDX Inc., a Boulder developer of genetic assays for cancer patients, for $1.4 billion, ...

Hi, everyone. Good afternoon. Thanks for joining us here. If you don't know me, my name is Andrew Brackmann, I cover diagnostics for William Blair. This afternoon, we have Invitae joining us. We have ...

Shares of Invitae Corp. traded 40% higher after the company reported it will acquire ArcherDX in a combination cash and stock deal valued at around $1.4 billion. Advanced medical genetics company ...

Yes. Thank you. Great. We are just about at the time here 1:30. So sorry about that. Welcome. Obviously, day one of the TD Cowen Health Care Conference. I am Dan Brennan. One of the tools analyst here ...

We recently compiled a list of the 10 Best Stocks to Buy and Hold For 5 Years According to Cathie Wood. In this article, we are going to take a look at where Invitae Corporation (OTC:NVTAQ) stands ...

Invitae Corporation beats earnings expectations. Reported EPS is $-0.1, expectations were $-0.3. Operator: Good afternoon, and welcome to the Invitae Third Quarter 2023 Financial Results Conference ...

Labcorp beats Q2 profit and revenue estimates on demand for health tests Labcorp beat Wall Street expectations for second-quarter profit and revenue on Thursday on strong demand for its diagnostic ...

This week, Invitae put out a press release highlighting the insights Praxis Precision Medicines was getting from Invitae's Citizen platform. The platform enables companies to get medical history data ...

Invitae Corporation (NYSE: NVTA), which specializes in medical genetic testing, saw its shares climb as high as 23% this week, according to data from S&P Global Intelligence. The stock closed at $2.30 ...